bioengineer.org /1 month ago

Platinum Chemotherapy, Not PARP Inhibitors, Emerges as the Main Driver of Blood Clone Expansion

New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous recombination deficiency unexpect...

Read source
genengnews.com /2 weeks ago

Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors

NYU Grossman School of Medicine researchers found that DNA-copying problems at a small set of chromosome sites can determine how cancer cells respond to PARP inhibitors, pointing t...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.